Canada - English - Health Canada

baxter corporation - cyclophosphamide - powder for solution - 500mg - cyclophosphamide 500mg - antineoplastic agents

Canada - English - Health Canada

baxter corporation - cyclophosphamide - powder for solution - 1000mg - cyclophosphamide 1000mg - antineoplastic agents

Canada - English - Health Canada

baxter corporation - cyclophosphamide - powder for solution - 2000mg - cyclophosphamide 2000mg - antineoplastic agents

Canada - English - Health Canada

sandoz canada incorporated - etoposide - solution - 20mg - etoposide 20mg - antineoplastic agents

Canada - English - Health Canada

strides pharma canada inc - etoposide - solution - 20mg - etoposide 20mg - antineoplastic agents

Canada - English - Health Canada

accord healthcare inc - mitomycin - powder for solution - 20mg - mitomycin 20mg - antineoplastic agents

European Union - English - EMA (European Medicines Agency)

teva b.v. - imatinib mesilate - dermatofibrosarcoma; gastrointestinal stromal tumors; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastic agents - imatinib teva b.v. is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment., paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis., adult patients with ph+ cml in blast crisis., adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy., adult patients with relapsed or refractory ph+ all as monotherapy.,  adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements., adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. , the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib teva b.v. is indicated for: , the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist)., the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatment., the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited. there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.,

Canada - English - Health Canada

hikma canada limited - mitomycin - powder for solution - 20mg - mitomycin 20mg

Canada - English - Health Canada

accord healthcare inc - cyclophosphamide - powder for solution - 500mg - cyclophosphamide 500mg

Canada - English - Health Canada

accord healthcare inc - cyclophosphamide - powder for solution - 1000mg - cyclophosphamide 1000mg